DiGiovanni J
Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Smithville 78957, USA.
Prog Clin Biol Res. 1995;391:195-212.
Two genetic models that could explain all of the current data are depicted in Figure 4, although it should be stressed that proof of any model will require additional genetic analyses. The first model (Model A) indicates that one or more loci controlling responsiveness to TPA are also responsible for directly controlling responsiveness to other classes of skin tumor promoters such as BzPo and Chr. We have called this locus the Pms locus (for skin tumor promotion sensitivity). The differences between compounds in the magnitude of their promoting ability may reside in the inability to activate a full set or compliment of Pms loci. Genetic differences may reside in a critical Pms locus that is necessary for tumor promotion by all chemical promoters. Alternatively, the current data could be interpreted as showing that different genes responsible for high sensitivity to promotion by diverse promoting agents act on a pathway(s) common to promotion in mouse epidermis (Model B). In this case, the Pms locus would represent a common biochemical/molecular pathway where different responses mediated by different types of promoters ultimately converge and lead to the process of tumor promotion in mouse skin. Directly testing either of the above models will require analyses of progeny from appropriate segregating crosses among the various stocks and strains used in the present study. Model B could help explain several experimental observations. First, SSIn mice, while still retaining a fairly high sensitivity to skin tumor promotion with Chr relative to other inbred strains (i.e., DBA/2, C57BL/6), have lost their increased sensitivity to this anthrone derivative relative to SENCAR mice. SSIn were developed through a process of inbreeding starting with the current outbred SENCAR and employing a selection scheme using DMBA initiation and TPA promotion similar to that originally devised by Boutwell (1964). Second, C57BL/6 mice, although relatively resistant to TPA, chrysarobin and BzPo, are somewhat peculiar in their high resistance to standard promotion protocols using TPA (DiGiovanni et al., 1991). Indirectly, these observations suggest that different genes may regulate some responses to particular types of promoting agent. For example, perhaps the induction of a oxidant response by phorbol esters would represent a specific response to this class of tumor promoters. A testable prediction from these observations is that it may be possible to selectively breed for mouse lines more sensitive and/or resistant to specific classes of promoting agents.
图4展示了两种能够解释当前所有数据的遗传模型,不过需要强调的是,任何模型的验证都需要进一步的遗传分析。第一种模型(模型A)表明,一个或多个控制对佛波酯(TPA)反应性的基因座也直接负责控制对其他类皮肤肿瘤启动剂(如苯并芘(BzPo)和补骨脂素(Chr))的反应性。我们将这个基因座称为Pms基因座(用于皮肤肿瘤启动敏感性)。不同化合物在促进能力大小上的差异可能在于无法激活完整的一组Pms基因座或其互补物。遗传差异可能存在于一个关键的Pms基因座中,这是所有化学启动剂促进肿瘤形成所必需的。或者,当前的数据也可以解释为表明,负责对不同启动剂高度敏感的不同基因作用于小鼠表皮启动的共同途径(模型B)。在这种情况下,Pms基因座将代表一条共同的生化/分子途径,不同类型启动剂介导的不同反应最终在此汇聚,并导致小鼠皮肤中的肿瘤启动过程。直接测试上述任何一个模型都需要分析本研究中使用的各种品系和菌株之间适当的分离杂交后代。模型B可以帮助解释一些实验观察结果。首先,SSIn小鼠虽然相对于其他近交系(即DBA/2、C57BL/6)对补骨脂素诱导皮肤肿瘤仍保持相当高的敏感性,但相对于SENCAR小鼠,它们对这种蒽酮衍生物的敏感性增加已经丧失。SSIn是通过从当前的远交SENCAR开始近亲繁殖的过程,并采用类似于Boutwell(1964)最初设计的使用二甲基苯并蒽(DMBA)启动和佛波酯(TPA)促进的选择方案培育而成。其次,C57BL/6小鼠虽然对佛波酯、白降汞和苯并芘相对耐药,但它们对使用佛波酯的标准启动方案具有较高的耐药性,这有点特殊(DiGiovanni等人,1991)。这些观察结果间接表明,不同的基因可能调节对特定类型启动剂的某些反应。例如,也许佛波酯诱导的氧化应激反应代表了对这类肿瘤启动剂的特异性反应。从这些观察结果中可检验的预测是,有可能选择性培育出对特定类启动剂更敏感和/或更耐药的小鼠品系。